Drugs / GOLOTIMOD
GOLOTIMOD
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00968357 | Sep 2009 → Jan 2011 | chronic hepatitis C virus infection | SciClone Pharmaceuticals | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT01247246 Comparator | Dec 2010 → Jun 2014 | mucositis | SciClone Pharmaceuticals | Unknown | No outcome recorded |
| Phase 2 | NCT00756951 Comparator | Sep 2008 → ? | chemotherapy-induced oral mucositis, head and neck cancer | SciClone Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GOLOTIMOD | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103812 ↗ |
| Known as | SCV 07 | “clinical trial material; (placebo or SCV 07) at doses of 0 (placebo), 0.1, 0.3, and 1.0 mg/kg will be administered sc” NCT01247246 ↗ |
| Known as | γ-D-glutamyl-L-tryptophan | “SCV-07 (γ-D-glutamyl-L-tryptophan) is a new immunomodulatory compound that has been developed and patented both for composition and immunomodulatory use and is a synthetic dipeptide.” NCT00968357 ↗ |
| Action | Inhibit | “block signal transducers and activator of transcription 3 (STAT3) mediated signaling” NCT00968357 ↗ |
| Modality | Peptide | “is a synthetic dipeptide” NCT00968357 ↗ |
| Route | Subcutaneous | “1.0 mg/kg per day administered SC” NCT00968357 ↗ |
| Target | STAT3 | “block signal transducers and activator of transcription 3 (STAT3) mediated signaling” NCT00968357 ↗ |